Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

Clinical trial NCT07116967 · RECRUITING

Trial details

NCT number: NCT07116967
Sponsor: Bristol-Myers Squibb
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Plaque Psoriasis

Start date: 2025-09-22
Primary completion: 2031-01-16
Enrollment: 3040

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.